Published in Medical Letter on the CDC and FDA, November 6th, 2005
Scientists in the United States report, "The role of C-reactive protein (CRP) in heart failure is not well studied. We assessed the prognostic value of CRP in patients randomized in Val-HeFT (Valsartan Heart Failure Trial) and studied changes in CRP that were associated with valsartan."
I.S. Anand and colleagues of the Veterans Administration Medical Center in Minneapolis explained, "Characteristics of patients with baseline CRP levels above and below the median value were compared. Univariable and multivariable Cox proportional...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.